Sun BioPharma, Inc. to Participate in the 11th Annual Craig-Hallum Alpha Select Conference
10 Novembro 2020 - 10:00AM
Sun BioPharma, Inc. (Nasdaq:SNBP), a clinical stage
biopharmaceutical company developing disruptive therapeutics for
the treatment of patients with pancreatic cancer, today announced
it will participate in the 11th Annual Craig-Hallum Alpha Select
Conference to be held virtually on Tuesday, Nov 17, 2020.
Management will host one-on-one meetings with investors who are
registered to attend the conference. For more information about the
conference or to schedule a virtual one-on-one meeting with
management, please contact your Craig-Hallum representative.
Alternatively, please contact James@HaydenIR.com .
About SBP-101SBP-101 is a proprietary polyamine
analogue designed to induce polyamine metabolic inhibition (PMI) by
exploiting an observed high affinity of the compound for the
exocrine pancreas and pancreatic ductal adenocarcinoma. The
molecule has shown signals of tumor growth inhibition in clinical
studies of US and Australian metastatic pancreatic cancer patients,
suggesting complementary activity with an existing FDA-approved
chemotherapy regimen. In clinical studies to date, SBP-101 has not
shown exacerbation of the typical chemotherapy-related adverse
events of bone marrow suppression and peripheral neuropathy. The
safety data and PMI profile observed in Sun BioPharma’s current
clinical trial provides support for continued evaluation of the
compound in a randomized clinical trial.
About Sun BioPharmaSun BioPharma Inc. is a
clinical-stage biopharmaceutical company developing disruptive
therapeutics for patients with urgent unmet medical needs. The
Company’s initial product candidate is SBP-101 for the treatment of
patients with metastatic pancreatic ductal adenocarcinoma, the most
common type of pancreatic cancer. Sun BioPharma Inc. is dedicated
to treating patients with pancreatic cancer and fully exploring
SBP-101’s potential for efficacy in combination with other agents
and in treating other types of cancer. SBP-101 was invented
by Raymond J. Bergeron, Ph.D., a Distinguished Professor Emeritus
at the University of Florida. Sun BioPharma has scientific
collaborations with pancreatic disease experts at Cedars Sinai
Medical Center in Los Angeles, the University of Rochester in New
York, Scripps MD Anderson Cancer Center in San Diego, California,
the University of Florida, the Austin Health Cancer Trials Centre
in Melbourne, Australia, the Ashford Cancer Centre in Adelaide,
Australia, the Blacktown Cancer and Haemotology Centre in Sydney,
Australia and the John Flynn Private Hospital in Tugun, Queensland,
Australia. The Company’s independent Data Safety Monitoring Board
(DSMB) is Chaired by James Abbruzzese, MD, Professor of Medicine,
and Chief, Division of Medical Oncology at Duke University School
of Medicine. Professor David Goldstein, FRACP, Senior Staff
Specialist at the Prince Henry & Prince of Wales Hospital /
Cancer Care Centre in Sydney, Australia is Co-Chair of the DSMB.
Further information can be found at: www.sunbiopharma.com. Sun
BioPharma’s common stock is listed on the Nasdaq Capital Market
under the symbol SNBP.
Contact Information:
Investors:
James Carbonara
Hayden IR
(646) 755-7412
James@haydenir.com
Media:
Tammy Groene – Sun BioPharma, Inc.
952-479-1196
IR@sunbiopharma.com
Sun BioPharma (NASDAQ:SNBP)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Sun BioPharma (NASDAQ:SNBP)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
Notícias em tempo-real sobre Sun BioPharma Inc da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de